drugset / Trial / NCT05546411
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of care FOLFIRINOX treatment for pancreatic cancer. The names of the study interventions involved in this study are: * NIS793 * FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluorouracil, Irinotecan, and Oxaliplatin) Other interventions may include: * Chemoradiation Therapy * Surgery
Timeline
- Start
- 2023-01-06
- Primary completion
- 2023-08-16
- Completion
- 2023-10-13
Outcome
Outcome not reported
Stopped: “Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are stopping all clinical development of NIS793 in pancreatic cancer, effective immediately.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NISEVOKITUG | Monoclonal antibody | — | Intravenous |
| Background | 5-Fluorouracil (5-FU) | Small molecule | — | Intravenous |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |